Zacks Research Has Bearish Forecast for PLX FY2025 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at Zacks Research cut their FY2025 earnings per share estimates for Protalix BioTherapeutics in a research note issued on Tuesday, February 3rd. Zacks Research analyst J. Vandermosten now expects that the company will post earnings per share of ($0.04) for the year, down from their prior estimate of $0.02. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics’ Q4 2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.06) EPS and FY2027 earnings at $0.08 EPS.

Separately, HC Wainwright reduced their price objective on shares of Protalix BioTherapeutics from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 21st. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Protalix BioTherapeutics presently has an average rating of “Buy” and a consensus price target of $12.00.

Protalix BioTherapeutics Stock Performance

Shares of PLX opened at $2.89 on Thursday. The firm has a market cap of $232.42 million, a PE ratio of -22.23 and a beta of -0.21. Protalix BioTherapeutics has a twelve month low of $1.32 and a twelve month high of $3.10. The firm’s 50 day moving average price is $1.98 and its 200 day moving average price is $1.93.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd purchased a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at approximately $26,000. NewEdge Advisors LLC bought a new position in Protalix BioTherapeutics in the first quarter worth $39,000. BNP Paribas Financial Markets lifted its position in Protalix BioTherapeutics by 126.5% during the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock valued at $34,000 after buying an additional 8,498 shares during the period. Virtu Financial LLC purchased a new position in Protalix BioTherapeutics during the third quarter valued at $37,000. Finally, Cascade Financial Partners LLC bought a new stake in shares of Protalix BioTherapeutics during the 2nd quarter valued at $25,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Insiders Place Their Bets

In other Protalix BioTherapeutics news, CEO Dror Bashan acquired 56,000 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were purchased at an average cost of $1.81 per share, for a total transaction of $101,360.00. Following the transaction, the chief executive officer owned 188,516 shares in the company, valued at $341,213.96. This represents a 42.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.50% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.